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Visceral leishmaniasis is an emerging neglected tropical disease (NTD) caused by the protozoan Leishmania infantum in the countries
bordering theMediterraneanBasin. Currently there is no effective vaccine against this disease, and the therapeutic approach is based
on toxic derivatives of SbV. Therefore, the discovery of new therapeutic targets and the development of drugs designed to inhibit them
comprise an extremely important approach to fighting this disease.DNA topoisomerases (Top) have been identified as promising tar-
gets for therapy against leishmaniasis. These enzymes are involved in solving topological problems generated during replication, tran-
scription, and recombination ofDNA. Being unlike that of themammalian host, type IBDNA topoisomerase (TopIB) fromLeishma-
nia spp. is a unique bisubunit protein, whichmakes it very interesting as a selective drug target. In the present investigation,we studied
the effect of twoTopIBpoisonswith indenoisoquinoline structure, indotecan andAM13-55, on amurineBALB/cmodel of infected
splenocytes with L. infantum, comparing their effectiveness with that of the clinically tested leishmanicidal drug paromomycin. Both
compounds have high selectivity indexes comparedwith uninfected splenocytes. SDS-KCl-precipitableDNA-protein complexes in
Leishmania promastigotes and in vitro cleaving assays confirmed that these drugs are Top poisons. The inhibitory potency of both
indenoisoquinolines on L. infantum recombinant TopIBwas assessed in vitro, with results showing that indotecanwas themost active
compound, preventing the relaxation of supercoiledDNA. Experimental infections in susceptible BALB/cmice treatedwith 2.5mg/kg
bodyweight/day once every other day for a total of 15 days showed that indotecan clearedmore than 80%of the parasite burden of the
spleen and liver, indicating promising activity against visceral leishmaniasis.
Neglected tropical diseases (NTD) produced by vector-borneprotozoa are mostly prevalent in underdeveloped and poor
countries, causing an estimated 4.1 million disability-adjusted life
years (DALYs) lost (16). However, in developed countries, where
these diseases were unknown or had been eradicated for a long
time, an unexpected new scenario has appeared. Increased tourist
exchange, soldiers deployed in countries where these diseases are
endemic, migratory fluxes, and eventually climate changes, along
with other pandemics, are challenging the apparent safety of rich
populations (26, 30). Since NTDs are prevalent in low-income
countries, large pharmaceutical companies have neglected re-
search and development of new drugs. Therefore, old compounds
that are losing efficacy are still in use. These compounds have
undesirable toxic effects, and their dosage schedules are complex
and repetitive, which compromises patient compliance (7).
Visceral leishmaniasis is an NTD increasingly affecting Euro-
pean countries because of the massive flows of immigrants from
NorthAfrica (18). Its etiologic agent,Leishmania infantum, infects
domestic dogs (canine leishmaniasis), which act as reservoir, and
it is transmitted to humans through sandfly bites (20). For de-
cades, the first-line treatment of this disease consisted of the old-
fashioned and toxic drugs derived from pentavalent antimony
(SbV) (1). Recently, safer and more effective drugs, such as am-
photericin B, miltefosine, and paromomycin, are replacing SbV,
despite the fact that they are not devoid of undesirable side effects
and cannot be administered during pregnancy (8, 9). For these
reasons, the search for new compounds against this disease is very
much needed. Since the beginning of this century, DNA topo-
isomerase IB (TopIB) has been identified as a potential target in
therapy against Leishmania and other trypanosomatids (3, 5, 6).
The choice of this target is based on two main reasons: (i) the
enzyme has an increased expression during the rapidly dividing
cycle of the pathogen, similar to the case with tumor cells, and
especially (ii) the pathogen’s enzyme is structurally different from
that of the host (35).
Our research group found that Leishmania donovani TopIB
(LdTopIB) was atypically composed of two different subunits, en-
coded by different genes, that have to be assembled in the patho-
gen to reconstitute the active enzyme. One of the subunits con-
tains the four amino acids of the active site, which is fully
conserved from a phylogenetic point of view (35). The other sub-
unit contains the catalytic amino acid (Tyr222), which acts by
breaking one DNA strand by a specific nucleotide sequence (13).
All of these features have also been found in the other protozoan-
borne NTDs pathogens: Trypanosoma brucei, the agent responsi-
ble for sleeping sickness inAfrica (11), andT. cruzi, responsible for
Chagas’ disease in South America (36). However, despite the fact
that these enzymes conserve their catalytic domains unchanged,
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they display two nonconserved regions, one at the C-terminal end
of the large protomer and the other at the N-terminal end of the
small protomer, which are extremely important in sensitivity to
topoisomerase poisons (12). These compounds act by stabilizing
enzyme-DNA complexes, preventing the religation step and even-
tually producing single-strand breaks when they collide with the
replication fork during DNA synthesis (22). The most studied
TopIB poison comprises camptothecin (CPT) and its derivatives,
including topotecan and the prodrug irinotecan, which are being
used against certain tumors (10, 32). Other, non-CPT TopIB poi-
sons are indolocarbazoles, such as the DNA-intercalating drug
rebeccamycin, and indenoisoquinolines, which were initially de-
veloped as antitumor compounds with an improved ability to
stabilize cleavage complexes (2, 25).
There are several promising indenoisoquinolines being stud-
ied for therapy targeting tumor processes and more recently for
therapy against experimental African trypanosomiasis (4). In this
article, we show for the first time the effects of two indenoiso-
quinolines, indotecan and AM13-55, on the viability of free-living
promastigotes and amastigote-infected murine splenocytes. For this
purpose,weusedamodifiedstrainofL. infantum transfectedwith the
gene encoding the infrared protein IFP1.4 from the extremophilic
bacteriumDeinococcus radiodurans (31).This fluorescent pathogenic
strain retains its virulence unaffected and allows studies of high per-
formance in both free-living promastigotes and ex vivo spleen ex-
plants,whereparasite growth conditions resemble anatural infection
environment.The results provided in thisworkdemonstrate thehigh
selectivity indexes of bothmolecules in vitro and the promising ther-
apeutic potential of indotecan against visceral leishmaniasis.
MATERIALS AND METHODS
Reagents and culture media. Pyrococcus furiosus (Pfu) and Klenow poly-
merases and restriction enzymes were acquired from Roche (Roche
Farma SA, Spain) and GE Healthcare (Spain). T4 DNA ligase was ob-
tained from Stratagene (La Jolla, California). Cell culture media were
purchased from Sigma-Aldrich (Spain). The indenoisoquinolines indote-
can and AM13-55 (Fig. 1) were kindly provided by Mark Cushman, De-
partment of Medicinal Chemistry and Molecular Pharmacology, Purdue
University. Primers for PCR amplification were from Sigma Genosys
(United Kingdom).
Generation of an infrared fluorescent L. infantum strain. L. infan-
tum promastigotes (BCN150 strain) were obtained by J. M. Requena
(Centro de BiologíaMolecular SeveroOchoa,Madrid Spain). The 987-bp
IFP1.4 coding region—an improved monomeric infrared fluorescent
protein derived from Deinococcus radiodurans (31)—was amplified by
PCR from the IFP1.4_pcDNA3 vector, a gift fromRoger Y. Tsien (Depart-
ment of Pharmacology, Department of Chemistry and Biochemistry,
University of California, San Diego), using the forward primer 5=CCGC
TCGAGCCATGGCCACCATGGCTCGGGACCCTCTGCC3= and the
reverse primer 5=ATAAGAATGCGGCCGCTCATTTATACAGCTCGTC
CATTCC3=. The amplified fragmentwas digestedwith BglII andNotI and
assembled into the expression vector pLEXSY-2-HYG (Jena Bioscience
GmbH,Germany), whichwas previously digestedwith the same enzymes.
The resultant plasmid was named pLEXSY-IFP1.4. Parasites were electro-
porated with the large SwaI targeting fragment from pLEXSY-IFP1.4 and
selected on semisolid media as previously described (27). Many clonal
lines were obtained, and correct integration into the 18s rRNA locus was
confirmed by PCR analysis. The transformant strain was routinely cul-
tured at 26°C in M199 medium supplemented with 25 mM HEPES (pH
6.9), 10mMglutamine, 7.6mMhemin, 0.1mMadenosine, 0.01mM folic
acid, 1RPMI 1640 vitaminmix (Sigma), 10% (vol/vol) heat-inactivated
fetal calf serum (FCS), and antibiotic cocktail (50 U/ml penicillin and 50
g/ml streptomycin).
Ex vivo splenic explant cultures. BALB/c mice were inoculated intra-
peritoneally with 108 L. infantum purified metacyclic promastigotes.
Briefly, infective promastigotes were isolated from stationary-phase cul-
ture by negative selection with peanut agglutinin (29). Five weeks postin-
fection, spleens were aseptically dissected, washed in cold phosphate-
buffered saline (PBS), and placed in petri dishes. Small pieces were
obtained by using a scalpel. In order to obtain a single-cell suspension,
tissuewas incubatedwith 5ml of 2mg/ml collagenaseD (Roche) prepared
in buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, and 1.8mMCaCl2) for 20min at 37°C. A cell suspension contain-
ing traces of spleenmass was gently passed through a 100-mcell strainer
to remove tissue fragments (21). Splenocytes were washed twice with PBS
by centrifugation (500  g for 7 min at 4°C) and resuspended in RPMI
medium supplementedwith 10%FCS, 1mM sodiumpyruvate, 1RPMI
vitamins, 10 mM HEPES, and 50 U/ml penicillin and 50 g/ml strepto-
mycin at 37°C with 5% CO2. Cells were counted and diluted at different
cell densities. Cells were seeded until confluence, and different concentra-
tions of the studied indenoisoquinolines were administered to the ex-
plants for 48 h. The viability of infecting amastigotes was assessed by
registering the fluorescence emission at 708 nm in an Odyssey (Li-Cor)
infrared imaging system. The cytotoxicities of the drugs were assessed on
uninfected ex vivo explants after 48 h of incubation, using the alamarBlue
staining method according to the manufacturer’s recommendations.
Recombinant Leishmania infantum TopIB. Cloning of Leishmania
infantum TopIB (LiTopIB) open reading frames (ORFs) (encoding large
and small subunits) and expression and purification of the enzyme were
carried out as previously described for LdTopIB (35). Briefly, a Saccharo-
myces cerevisiae EKY3 strain deficient in TopIB activity (MAT ura3-52
his3200 leu21 trp163 top1 TRP1) was transformed by the lithium
acetate method (15) with the bicistronic pESC-URA vector, which carries
both LiTopIBORFs. Single colonies were incubated overnight in synthetic
complete (SC)-uracil medium with 2% (wt/vol) dextrose. Since dextrose
tracesmay interfere with the expression of the protein, yeast cultures were
incubated in SC-uracil medium supplemented with 2% (wt/vol) raffinose
for 24 h prior to a 6-h induction with 2% (wt/vol) galactose. Yeasts were
FIG 1 Chemical structures of the indenoisoquinolines indotecan and AM13-
55, used in the present study.
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harvested, washed with cold 1TEEG buffer (50mMTris–HCl [pH 7.4],
1 mM EDTA, 1 mM EGTA, and 10% glycerol) and resuspended in 15 ml
of the same buffer supplemented with 0.2 M KCl and a protease inhibitor
cocktail (Roche Farma SA, Spain). The cells were subjected to one freeze/
thaw cycle at 80°C and lysed by vortexing in a glass bead beater at 4°C.
Protein extracts were obtained by centrifugation at 15,000 g for 45 min
at 4°C. Yeast extracts were sequentially precipitated with two increasing
concentrations of ammonium sulfate (35 and 75%, respectively). The
second precipitate supernatant was loaded on a P-11 phosphocellulose
column (Whatman International Ltd., England), which was equilibrated
following themanufacturer’s indications. The LiTopIB proteinwas eluted
at 4°C with a discontinuous gradient of KCl (0.2, 0.4, 0.6, 0.8, and 1M) in
TEEG buffer supplemented with 0.1mg/ml sodium bisulphite, 0.8mg/ml
sodiumbisulfite, and the protease inhibitor cocktail. Active fractions were
loaded on a phenyl-Sepharose column (Sigma-Aldrich) with a discontin-
uous inverse gradient of ammonium sulfate (1, 0.8, 0.6, 0.4, and 0.2 M).
Elution was performed with subsequent Centricon (Millipore) concen-
tration.
Supercoiled plasmidDNATopIB-mediated cleavage assay.The sen-
sitivity of LiTopIB to indotecan, AM13-55, and CPT (used as a control
drug) was assayed by DNA cleavage assays. pBluescript SK() phagemid
DNA (pSK) was used as a nickable substrate. At least 100 U of purified
LiTopIB was incubated with 0.5 g of pSK DNA in 10 mM Tris-HCl
buffer (pH 7.5), 5 mM MgCl2, 5 mM dithiothreitol (DTT), 0.1 mM
EDTA, 15 g/ml bovine serum albumin, and 50 mMKCl. Different drug
concentrations in 1% (vol/vol) dimethyl sulfoxide (DMSO) (20-l reac-
tion volume) were also added. Following incubation for 4 min at 25°C,
reactions were then stopped with up to 1% (wt/vol) SDS and incubated in
the presence of 1 mg/ml proteinase K for one extra hour at 37°C. Subse-
quently, samples were extracted with 1 volume of phenol-chloroform and
loaded on a 1% agarose gel containing ethidium bromide to a final con-
centration of 40 pg/l (17). The gel was run for 16 h at 4 V/cm, and the
images of cleavage productswere acquired using aG-Box system (Syngene
United Kingdom).
DNA relaxation assays. TopIB activity was assayed by the relaxation
of negatively supercoiled plasmid DNA. One unit of recombinant
LiTopIB was incubated with the corresponding drug for 15 min at 4°C.
Then, the reaction mixture, containing 0.5 g of supercoiled pSK DNA,
10mMTris-HCl buffer (pH 7.5), 5 mMMgCl2, 0.1 mMEDTA, 15g/ml
bovine serum albumin, and 50 mM KCl, in a total volume of 20 l, was
added. Reaction mixtures were incubated for 4 min at 25°C. Enzyme
reactions were stopped by the addition of up to 1% (wt/vol) SDS (final
concentration) and digested with 1 mg/ml proteinase K at 37°C during
one extra hour to remove the protein that remained linked to DNA frag-
ments. The extent of plasmid DNA relaxation was assessed in 1% agarose
gels by electrophoresis in 0.1 M Tris borate EDTA buffer (pH 8.0) at 2
V/cm for 16 h. Gels were visualized with UV illumination after ethidium
bromide (0.5 g/ml) staining. A further electrophoresis was run in the
presence of 0.1g/ml ethidium bromide in order to separate nickedDNA
from relaxed topoisomers (33).
SDS-KCl precipitation assay. For indenoisoquinoline-induced pro-
tein-DNA complex determination, L. infantum promastigotes, previously
labeled for 24 h with 0.5 Ci/ml [2-14C]thymidine, were exposed to dif-
ferent concentrations of CPT and indenoisoquinolines for 30 min (3).
Cells were pelleted and lysed by incubation at 60°C for 10 min in the
presence of 1.25% (wt/vol) SDS, 0.4 mg/ml salmon sperm DNA, and 5
mM EDTA. After the addition of 65 mM KCl, the reaction mixture was
incubated on ice for 60 min. The precipitate was harvested by filtering
through glass fiber paper (GF/C; Brandel Inc., Maryland), prewetted with
wash buffer (10mMTris-HCl, pH 8, 1mMEDTA, 100mMKCl), washed
(three times with 4 ml of wash buffer), and air-dried. After spotting 50 l
of the same density of labeled cell suspensions onto filter paper and pre-
cipitating nucleic acids using 5% (vol/vol) trichloroacetic acid, total in-
corporation of radioactivity into DNA was measured by using a liquid
scintillation counter (Beckman LS600A). All assays included vehicle drug
as a control. The formation of DNA fragments, as a percentage of total
labeledDNA,was calculated as follows: [(dpm in SDS-KCl drug dpm in
SDS-KCl solvent)/(dpm total incorporation)] 100.
Thymidine incorporation assay. Leishmania infantum promastigotes
(10 ml; 5  106 cells/ml) were incubated with [2-14C]thymidine (0.5
Ci/ml) in the presence of drug or solvent in thymidine-free complete
M199medium. Five hundred-microliter aliquots were removed after 2, 4,
8, 10, and 24 h and loaded on glass fiber paper (GF/C; Brandel Inc.,
MarylanD). 14C-labeled-DNA was precipitated using ice-cold 5% (wt/
vol) trichloroacetic acid and sequentially washed with PBS, 90% (vol/vol)
ethanol, and 70% (vol/vol) ethanol. Radioactivity was quantified by liquid
scintillation. CPT was used as a positive control.
Animals. Female BALB/c mice (ages 4 to 6 weeks) were purchased
from Harlan Ibérica Laboratories (Spain). All animal procedures were
approved by the University of Leon Subcommittee on Research Animal
Care.
Infective-stage metacyclic L. infantum promastigotes were isolated
from stationary-phase cultures (6 days old) by negative selection with
peanut agglutinin (29). Mice were infected with 107 metacyclic parasites
intravenously through the tail vein. Fourteen days later, once every 2 days
for 15 days, mice were administered a solution of indotecan or AM13-55
indenoisoquinolines diluted in DMSO (equivalent to a dose of 2.5 mg/kg
of body weight per injection) intraperitoneally, for a total of eight doses.
Five days after the last treatment, the mice were euthanized, organs were
removed, and parasite loads were determined by limiting-dilution assay
(34). Briefly, a suspension of 20 mg of either spleen or liver was prepared
by grinding the tissue in 1 ml of Schneider’s medium (Gibco BRL) con-
taining 20% (vol/vol) heat-inactivated FCS in the presence of streptomy-
cin and penicillin. This suspension was further diluted to reach a final
concentration of 1 mg/ml. The parasite burden was determined by the
limiting-dilution method after a 10-day period of parasite growth. The
parasite burden was expressed as the number of free-living promastigotes
per gram of wet tissue and compared to that for the nontreated group.
RESULTS AND DISCUSSION
Recent studies showed that the CPT derivatives topotecan, SN38,
and especially gimatecan are powerful leishmanicide agents. In
vitro assays demonstrated that they act by trapping bothDNA and
LiTopIB in reversible ternary complexes, producing precipitable
SDS-KCl material when free-living promastigotes are incubated
in the presence of these drugs (Prada et al., in press [23]). These
compounds had good selectivity indexes when their cytotoxicity
on mammalian cells (uninfected splenocytes) was compared to
that from isolated ex vivo splenic explants of BALB/cmice infected
with L. infantum. However, none of these compounds were more
selective than miltefosine, the only effective oral treatment for
visceral and cutaneous leishmaniasis (9). The use of a model of
mouse splenocytes infected with an L. infantum strain expressing
IFP1.4 permits high-throughput screening of compounds under
conditions that resemble those found in the animal, including the
complete range of immune host cells, infected macrophages, and
fibroblasts (28).
Screening of indenoisoquinolinic compounds. The initial
screening of new indenoisoquinolinic compounds was performed
on free-living promastigotes: the infrared fluorescent protein 1.4
(IRF1.4)-L. infantum (BCN150) strain. To quantify cytotoxicities
of the test compounds, we utilized peritoneal BALB/cmousemac-
rophages. We first excluded compounds, that fell below an arbi-
trary cytotoxicity threshold in the peritonealmacrophage cultures
(50% inhibitory concentration [IC50] of 10 M) (data not
shown), and after exclusion of nine indenoisoquinolinic com-
pounds (see Fig. S1 in the supplemental material), only two new
drugs were kept for further validation studies (Fig. 1).
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For these two compounds, antileishmanial activity (50% effec-
tive concentration [EC50]) was determined in the ex vivo splenic
explant system. Comparison of these EC50s with cytotoxicity
(IC50) values in the uninfected ex vivo splenic explant allowed
determination of an in vitro selectivity index (SI) (IC50/EC50) (Ta-
ble 1). As a positive control, we have used both paromomycin and
CPT. Paromomycin has demonstrated a good selectivity index in
the same system (Prada et al., in press [23]).
CPT and both indenoisoquinolines (indotecan and AM13-55)
were much more effective in preventing the proliferation of pro-
mastigotes and development of infection in splenocytes than
paromomycin, an aminoglycoside antibiotic used in clinical practice
against human leishmaniasis. The IC50 of paromomycin was esti-
mated to be 9.20Mformouse ex vivo splenic explants infectedwith
L. infantum, whereas the IC50 was 0.1M for indotecan and AM13-
55. Only CPT was more effective (IC50  0.03 M) at killing the
parasites. To estimate the cytotoxicity onmammalian cells and there-
fore determine selectivity indexes of the studied compounds, we pre-
parednoninfected ex vivo splenic explant. These cellswere exposed to
different concentration ranges of the drugs for 48 h, and the viability
was determined by the alamarBlue method. Dose-response curves
were fitted by nonlinear analysis using the Sigma-Plot statistical soft-
ware package, showing that the least toxic compound was paromo-
mycin (IC5015.70mM), followedby indotecan(IC5057.16M)
and AM13-55 (IC50 48.37 M). Selectivity indexes of each com-
pound were calculated as the ratio between the IC50s with the unin-
fected explants system versus the IC50s with infected ex vivo splenic
explants. Both indenoisoquinolines have very high selectivity in-
dexes, 571.6 for indotecan and 483.7 for AM13-55, which are very
much higher than those of CPT-related compounds andmiltefosine
(23) but less than that of paromomycin (the safest compound tested,
with a selectivity index of 1,706.5).
Indotecan and AM13-55 induce TopI-DNA convalent com-
plexes. Figure 2A shows the induction of DNA cleavage com-
TABLE 1 IC50 calculation after 48-h period of exposure to selected













Paromomycin 42.41 1.65 M 9.20 0.01 M 15.70 3.54 mM 1,706.5
Camptothecin
(22)
1.12 0.13 M 0.03 0.01 M 0.62 0.13 M 20.7
Indotecan 0.10 0.08 M 0.10 0.05 M 57.16 6.01 M 571.6
AM13-55 1.02 0.09 M 0.10 0.37 M 48.37 3.68 M 483.7
a IC50 at 48 h of the compounds selected in freshly uninfected splenocyte culture and
SI48h values between this cell line and infected splenocytes with L. infantum amastigotes
ex vivo were calculated from the dose-response curves determined in triplicate in
separate experiments after performing a nonlinear fitting with the SigmaPlot software
program.
b Mean SD.
c Selectivity index; SI48h, IC50 for amastigotes/IC50 for infected splenocytes.
FIG 2 Indotecan and AM13-55 induce TopI-DNA covalent complexes and inhibit supercoiled DNA relaxation. (A) Supercoiled plasmidDNATopIB-mediated
cleavage assay showing the displacement toward cleavage complexes mediated by both indenoisoquinolines and CPT on LiTopIB. Samples were run on a 1%
agarose gel containing ethidium bromide to a final concentration of 40 pg/l in order to separate supercoiled and relaxed DNA. The results are representative of
three independent trials. (B) Inhibition of supercoiled DNA relaxation by indotecan (top gel) and AM13-55 (bottom gel) mediated by human (left lanes)or
leishmanial (right lanes) TopIB. Reaction mixtures were incubated at 37°C in a final concentration of 150 M KCl and then stopped with SDS up to a final
concentration of 1% of reaction volume. Products were resolved in a 1% agarose gel and visualized by ethidium bromide staining. The results are representative
of three independent trials.
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plexes by indotecan andAM13-55 in the presence of TopI as tested
in supercoiled plasmidDNA (pSK). Both indotecan andAM13-55
induce DNA cleavage complexes in a pattern similar to that of
CPT but with differences in their relative intensities. The indote-
can cleavage complex showed the same strong intensity as CPT at
100 M, although the cleavage complex intensity is almost the
same in the range of 0.1 to 10 M. On the other hand, the
AM13-55 cleavage complex has lower intensities than those of
CPT, but the pattern resembles that of CPT, being proportional to
the drug concentration. We observed a dose-dependent increase
in nicked DNA for the three compounds, thus confirming the
TopIB-poisoning nature of both indenoisoquinolines (2, 4).
We also studied the potency for inhibiting DNA relaxation
activity, comparing the human and leishmanial TopIB enzymes.
The LiTopIB enzyme was more sensitive to indotecan and
AM13-55 than the human enzyme. Figure 2B (top panel) showed
that Leishmania TopIB was already inhibited at 80 nM indotecan.
However, 2.5 M was required to achieve the same effect on the
human enzyme. AM13-55 (Fig. 2B, lower panel) was a little bit less
efficient, inhibiting Leishmania TopIB at 0.15 M, while the hu-
man enzyme was not inhibited until 2.5 M.
These results suggest that the indenoisoquinolines indenote-
can andAM13-55 at pharmacologically relevant doses are primar-
ily TopI poisons, with DNA cleavage patterns exhibiting similar-
ities and differences from those of CPT, but they are much more
effective for Leishmania than for human enzyme.
Induction of TopI-DNA complexes by indotecan and
AM13-55 in L. infantum cultures. To determine whether indo-
tecan and AM13-55 induce TopI cleavage complexes in drug-
treated cells, we used the SDS-KCl precipitation assay. IFP1.4-L.
infantum (BCN150) promastigotes were exposed for 30 min to
different concentrations of CPT (used as a positive control), in-
dotecan, and AM13-55 in a concentration range from 0.1 to 90
M. After this time, stabilized protein-DNA complexes were
quantified by the SDS-KCl precipitationmethod. Figure 3A shows
that CPT produced an increasing amount of SDS-KCl-precipita-
ble complexes that were dependent on the concentration of drug
that was added up to a value close to 80% of total labeled DNA.
None of the indenoisoquinolines studied had such a potent effect
within the same concentration range. Indotecan and AM13-55
clearly showed an increase in the amount of SDS-KCl-precipitable
complexes, but unlike CPT, indotecan produced up to 20% la-
beled DNA at 10 M. AM13-55 reached up to 40% at the same
concentration. These results are higher than those obtained by
Bakshi and coworkers with three sets of indenoisoquinolines
against trypomastigotes of T. brucei (4). In that case, the inde-
noisoquinolines tested induced only up to 12% of cleavage com-
plexes from the total labeled DNA.
Since indotecan and AM13-55 inhibit DNA relaxation and in-
duce stabilization of DNA cleavage complexes, we performed a
competition study between CPT and both indenoisoquinolines in
order to evaluate the primary mediator of cell killing in Leishma-
FIG 3 Induction of TopI-DNA complexes by indotecan and AM13-55 in L. infantum cultures and DNA synthesis inhibition. SDS-KCl-precipitable enzyme-
DNA complexes at increasing concentrations of the drugs under study. (A) CPT, indotecan, andAM13-55 in promastigotes of L. infantum after 30min of growth
in the presence of different concentrations of drugs. Notice that for CPT the x scale is up to 10 M, whereas in the panels for indotecan and AM13-55,
concentrations reach 90 M. Results are expressed as means SE for at least three different experiments carried out in duplicate. (B) Indotecan and AM13-55
increase CPT-induced cleavable complex formation. Leishmania promastigotes were treated with 5 M indotecan, 5 MAM13-55, or 10 MCPT for 30 min
or with 5M indotecan or AM13-55 for 5 min prior to addition of 10MCPT, followed by an additional 25-min incubation; , P 0.01;  , P 0.05 (paired
Student t test). (C) Incorporation of [2-14C]thymidine into DNA of growing promastigotes in the presence of 1 MCPT (empty dots), 1 MAM13-55 (empty
triangles), 1M indotecan (solid triangles), or solvent (solid dots). The amount of labeled DNA is expressed as total cpm per assay at different time points (2, 4,
6, 8, 10, and 24 h). Results are expressed as means SE for at least three different experiments carried out in duplicate.
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nia. Figure 3B shows that 5 M concentrations of both tested
compounds were not able to prevent CPT-mediated TopIB-DNA
stabilization, thus pointing to the poisonous nature of both drugs
rather than interaction with DNA.
In order to assess the arresting effect of indotecan and
AM13-55 on DNA synthesis, 5  106 exponentially growing L.
infantum promastigotes were pulsed with 0.5 Ci [2-14C]thymi-
dine in the presence of 1 M CPT, 1 M AM13-55, 1 M indo-
tecan, or solvent (control). After a time lapse of 2, 4, 6, 8, 10, and
24 h, labeledDNAwas determined by scintillation counting. All of
the TopI poisons arrested DNA synthesis at all time points more
than 90% with no significant differences among them (Fig. 3C).
These results correlate well with those found by Cushman et al. in
2011 (19). They showed that indenoisoquilones with a large pri-
mary amine side chain, like indotecan and AM13-55, do not in-
tercalate into free DNA and do not suppress cleavage complex
formation at high concentrations, unlike those with a small pri-
mary amine (4, 19).
Indotecan and AM13-55 are used as therapeutic agents in a
visceral leishmaniasis murine model of infection with L. infan-
tum. To evaluate the therapeutic potential of indotecan and
AM13-55 in vivo, we performed an experimental infection with a
susceptible BALB/c mouse strain with L. infantum promastigotes
(wild-type strain). Seven million infective-stage metacyclic pro-
mastigotes were administered intravenously by the caudal vein to
15 healthymice that were 4 to 6 weeks old. By day 15 post-parasite
inoculation, mice were divided into three groups of five animals
each. Mice were treated with 0.5-ml solutions of indotecan or
AM13-55 in DMSO-saline, equivalent to 2.5 mg/kg body weight
per injection, intraperitoneally every 2 days for 15 days (total,
eight doses). As a control, indenoisoquinoline vehicle was admin-
istered.
Five days after the last administration, animals were killed by
cervical dislocation and spleens and livers were aseptically dis-
sected to determine the parasite load. This was determined by the
limiting-dilution assay. Each treatment group was compared to
the control, which had received only the vehicle in which the drug
had been dissolved.
Figure 4A shows the parasite burden in the group of mice
treated with 2.5 mg/kg of indotecan in spleen (upper panel) and
liver (lower panel). After the administration schedule was com-
pleted, a drastic reduction (P  0.001) of the number of trans-
forming amastigotes recovered from the target organs of drug-
treated animals was observed. On the other hand, mice treated
with the same dose of AM13-55 (Fig. 4B) showed that only the
spleen was efficiently cleared of infecting parasites, unlike the
liver, which retained the pathogen load at levels similar to those
for the untreated group (Fig. 4B). In a subsequent trial, 5.0 mg/kg
of body weight of AM13-55 was administered under the same
conditions as in previous experiments (data not shown). The par-
asite load was reducedmore than 90% in the spleen but not in the
liver, where the load remained unchanged. The resistance of liver
FIG 4 Indenoisoquinolines cleared tissue parasitic burdens in BALB/c mice experimentally infected with L. infantum. Three groups of five animals each were
challenged with 107 metacyclic promastigotes administered via the caudal vein. Fifteen days after infection, animals were injected intraperitoneally every 2 days
for a total of 15 days (eight doses total) with a dose of 2.5mg/kg bodyweight per injection of indotecan (A), AM13-55 (B), or the corresponding vehicle (a solution
of DMSO in sterilized saline solution). Mice were killed 5 days after the last treatment, and the spleens and livers were aseptically removed, weighted, and
homogenized in medium supplemented with 20% (vol/vol) FBS. After 10 days, transforming promastigotes were counted, and the limiting dilution was
considered to determine the parasitic burden of each organ. The results are representative of two independent trials; statistical differences were observed between
groups; , P 0.001 using the paired Student t test.
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macrophages to killing the parasites may be due to metabolic
transformations of the parent compound in the hepatic paren-
chyma on TopIB-inactive by-products.
Despite the fact that no definitive cure was achieved with indote-
can, our results are very similar to those found with 20 mg/kg body
weight of paromomycin alone or in combination with 200-mg/kg-
body-weight glucantime in experimental infections of BALB/c vis-
ceral leishmaniasis (14). Furthermore, both indotecan andAM13-55
weremore effective thanCPT(2.5mg/kgbodyweight), both free and
liposome encapsulated, in a murine model of L. donovani leishman-
iasis. The authors of that study found that parasite loads in livers and
spleenswere reducedby just55%onaveragewhen infectedmicewere
treated with this TopI poison (24).
In conclusion, we have proven that the two indenoisoquino-
lines analyzed have strong leishmanicidal activities both in vitro
(ex vivo splenic explant cultures) and in vivo (visceral leishmani-
osis murine model). These compounds act by stabilizing the
DNA-LiTopIB cleavage complexes and inhibiting the intrinsic re-
laxation activity of human and leishmanial TopIB enzymes. Indo-
tecan has a very high selectivity indexwith respect to host cells and
depleted the parasitic burden of the spleen and liver. These facts
make this compound an exceptional candidate for its develop-
ment as a new leishmanicidal drug with a better therapeutic pro-
file than others currently in use.
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